Hoegerle S, Altehoefer C, Ghanem N, Koehler G, Waller C F, Scheruebl H, Moser E, Nitzsche E
Department of Radiology, Division of Nuclear Medicine, Albert-Ludwigs University, Hugstetterstrasse 55, 79106 Freiburg, Germany.
Radiology. 2001 Aug;220(2):373-80. doi: 10.1148/radiology.220.2.r01au25373.
To evaluate fluorine 18 (18F) dopa positron emission tomography (PET) in comparison with established imaging procedures in gastrointestinal carcinoid tumors.
After evaluation of the normal distribution of 18F dopa, 17 patients with histologically confirmed tumors were examined with 18F dopa PET. Results of 2-[fluorine 18]fluoro-2-deoxy-D-glucose (FDG) PET, somatostatin-receptor scintigraphy, and morphologic imaging (computed tomography and/or magnetic resonance imaging) were available for all patients. Results of the procedures were evaluated by two radiologists and two nuclear medicine specialists, whose consensus based on all available histologic, imaging, and follow-up findings was used as the reference standard.
Ninety-two tumors were diagnosed: eight primary tumors, 47 lymph node metastases, and 37 organ metastases. 18F dopa PET led to 60 true-positive findings (seven primary tumors, 41 lymph node metastases, 12 organ metastases); FDG PET, 27 (two primary tumors, 14 lymph node metastases, 11 organ metastases); somatostatin-receptor scintigraphy, 52 (four primary tumors, 27 lymph node metastases, 21 organ metastases); and morphologic imaging, 67 (two primary tumors, 29 lymph node metastases, 36 organ metastases). This resulted in the following overall sensitivities: 18F dopa PET, 65% (60 of 92); FDG PET, 29% (27 of 92); somatostatin-receptor scintigraphy, 57% (52 of 92); morphologic procedures, 73% (67 of 92). Although the morphologic procedures were most sensitive for organ metastases, 18F dopa PET enabled best localization of primary tumors and lymph node staging.
18F dopa PET is a promising procedure and useful supplement to morphologic methods in diagnostic imaging of gastrointestinal carcinoid tumors.
评估氟-18（18F）多巴正电子发射断层扫描（PET）在胃肠道类癌肿瘤诊断中与现有成像方法相比的效果。
在评估18F多巴的正常分布后，对17例经组织学确诊肿瘤的患者进行了18F多巴PET检查。所有患者均有2-[氟-18]氟-2-脱氧-D-葡萄糖（FDG）PET、生长抑素受体闪烁显像及形态学成像（计算机断层扫描和/或磁共振成像）的结果。由两名放射科医生和两名核医学专家对检查结果进行评估，将基于所有可用的组织学、成像及随访结果达成的共识作为参考标准。
共诊断出92处肿瘤：8处原发性肿瘤、47处淋巴结转移灶和37处器官转移灶。18F多巴PET检查出60处真阳性结果（7处原发性肿瘤、41处淋巴结转移灶、12处器官转移灶）；FDG PET检查出27处（2处原发性肿瘤、14处淋巴结转移灶、11处器官转移灶）；生长抑素受体闪烁显像检查出52处（4处原发性肿瘤、27处淋巴结转移灶、21处器官转移灶）；形态学成像检查出67处（2处原发性肿瘤、29处淋巴结转移灶、36处器官转移灶）。由此得出以下总体敏感性：18F多巴PET为65%（92处中的60处）；FDG PET为29%（92处中的27处）；生长抑素受体闪烁显像为57%（92处中的52处）；形态学检查为73%（92处中的67处）。尽管形态学检查对器官转移最为敏感，但18F多巴PET对原发性肿瘤的定位及淋巴结分期效果最佳。
18F多巴PET在胃肠道类癌肿瘤的诊断成像中是一种有前景的检查方法，也是对形态学方法的有益补充。
